167414-75-7

Basic information

• Product Name: 3-OXO-3-(1-CBZ-PIPERIDIN-4-YL)-PROPIONIC ACID ETHYL ESTER
• Synonyms: Ethyl 3-(N-Cbz-piperidin-4-yl)-3-oxopropanoate;N-CBZ-4-Piperidinepropanoic acid,beta-oxo-,ethyl ester;Ethyl 3-(N-Cbz-4-piperidyl)-3-oxopropanoate;Ethyl 3-(1-Cbz-piperidin-4-yl)-3-oxopropanoate;Ethyl 3-(1-benzyloxycarbonylpiperidin-4-yl)-3-oxopropanoate;4-Piperidinepropanoic acid, β-oxo-1-[(phenylmethoxy)carbonyl]-, ethyl ester;Benzyl 4-(3-ethoxy-3-oxopropanoyl)
• CAS NO: 167414-75-7
• Molecular Formula: C₁₈H₂₃NO₅
• Molecular Weight: 333.38
• Mol File: 167414-75-7.mol

Chemical Properties

• Boiling Point: 461.8°Cat760mmHg
• Flash Point: 233.1°C
• Appearance: /
• Density: 1.19g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.533
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 10.39±0.20(Predicted)
• CAS DataBase Reference: 3-OXO-3-(1-CBZ-PIPERIDIN-4-YL)-PROPIONIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-OXO-3-(1-CBZ-PIPERIDIN-4-YL)-PROPIONIC ACID ETHYL ESTER(167414-75-7)
• EPA Substance Registry System: 3-OXO-3-(1-CBZ-PIPERIDIN-4-YL)-PROPIONIC ACID ETHYL ESTER(167414-75-7)

Safety Data

• Hazardous Substances Data: 167414-75-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-OXO-3-(1-CBZ-PIPERIDIN-4-YL)-PROPIONIC ACID ETHYL ESTER is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of drugs with analgesic, anti-inflammatory, or antiviral properties.
Used in Chemical Research and Development:
In the realm of chemical research and development, 3-OXO-3-(1-CBZ-PIPERIDIN-4-YL)-PROPIONIC ACID ETHYL ESTER is used as a building block to create new drug candidates, aiming to discover and develop novel therapeutic agents with improved efficacy and safety profiles.
Used in Medicinal Chemistry:
3-OXO-3-(1-CBZ-piperidin-4-yl)-propionic acid ethyl ester plays a crucial role in medicinal chemistry, where it is employed to explore and innovate new chemical entities with potential therapeutic benefits, enhancing the repertoire of available treatments for various health conditions.

InChI:InChI=1/C18H23NO5/c1-2-23-17(21)12-16(20)15-8-10-19(11-9-15)18(22)24-13-14-6-4-3-5-7-14/h3-7,15H,2,8-13H2,1H3

Upstream product

• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 141-78-6 ethyl acetate 
• 10314-99-5 benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate 
• 6148-64-7 ethyl potassium malonate 
• 501-53-1 benzyl chloroformate 
• 498-94-2 isonipecotic acid 

Downstream Products

• 1115491-17-2 benzyl 4-(2-amino-6-hydroxypyrimidin-4-yl)piperidin-1-carboxylate 
• 1266159-39-0 benzyl 4-(3-amino-4-(4-phenoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)-1-piperidinecarboxylate 
• 1266160-29-5 4-(4-phenoxyphenyl)-6-(piperidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-amine 
• 1413943-82-4 2-(4-(3-amino-4-(4-phenoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)piperidine-1-carbonyl)-3-cyclopropylacrylonitrile 
• 1413943-84-6 benzyl 4-(4-chloro-5-cyano-6-(4-phenoxyphenyl)pyridin-2-yl)piperidine-1-carboxylate 
• 1413943-85-7 3-(4-(3-amino-4-(4-phenoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)piperidin-1-yl)-3-oxopropanenitrile 
• 1413943-83-5 benzyl 4-(5-cyano-4-oxo-6-(4-phenoxyphenyl)-1,4-dihydropyridin-2-yl)piperidine-1-carboxylate 

Relevant articles and documents

Pyrazolopyrimidines as Potent Stimulators for Transient Receptor Potential Canonical 3/6/7 Channels

Transient receptor potential canonical 3/6/7 (TRPC3/6/7) are highly homologous receptor-operated nonselective cation channels. Despite their physiological significance, very few selective and potent agonists are available for functional examination of these channels. Using a cell-based high throughput screening approach, a lead compound with the pyrazolopyrimidine skeleton was identified as a TRPC6 agonist. Synthetic schemes for the lead and its analogues were established, and structural-activity relationship studies were carried out. A series of potent and direct agonists of TRPC3/6/7 channels were identified, and among them, 4m-4p have a potency order of TRPC3 > C7 > C6, with 4n being the most potent with an EC50 of 20 nM on TRPC3. Importantly, these compounds exhibited no stimulatory activity on related TRP channels. The potent and selective compounds described here should be suitable for evaluation of the roles of TRPC channels in the physiology and pathogenesis of diseases, including glomerulosclerosis and cancer.

Benzonaphthyrindines compounds and pharmaceutical compositions thereof and its application in pharmacy

The invention provides a pyrazolopyrimidine compound shown as a structural formula (I), a pharmaceutical composition taking the pyrazolopyrimidine compound as an active component, a preparation method of the pyrazolopyrimidine compound and the pharmaceutical composition as well as an application of the pyrazolopyrimidine compound and the pharmaceutical composition in preparation of a TRPC6 (Transient Receptor Potential Channel 6) adjustor probe medicine and related medicines for preventing and treating glomerulopathy and myocardial hypertrophy. The pyrazolopyrimidine compound and derivatives provided by the invention can be used to prepare medical preparations in various forms which comprise oral liquids, injections, pulmonary inhalation preparations and transdermal preparations, specifically injections, oral liquids, troches, capsules, granules, aerosols, dry powder inhalation, patches and the like.

TYROSINE KINASE INHIBITORS

The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, JAK3, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by

PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Partial GABAA Receptor Agonists. Synthesis and in Vitro Pharmacology of a Series of Nonannulated Analogs of 4,5,6,7-Tetrahydroisoxazolopyridin-3-ol

5-(4-Piperidyl)isoxazol-3-ol (4-PIOL, 10), a structural analog of 4-aminobutanoic acid (GABA, 1) and the GABAA agonist 4,5,6,7-tetrahydroisoxazolopyridin-3-ol (THIP, 5), is a low-efficiacy partial GABAA agonist.A number of com